Literature DB >> 24232507

Neuregulin-1 overexpression and Trp53 haploinsufficiency cooperatively promote de novo malignant peripheral nerve sheath tumor pathogenesis.

Stephanie N Brosius, Amy N Turk, Stephanie J Byer, Nicole M Brossier, Latika Kohli, Amber Whitmire, Fady M Mikhail, Kevin A Roth, Steven L Carroll.   

Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are Schwann cell-derived malignancies that arise from plexiform neurofibromas in patients with mutation of the neurofibromin 1 (NF1) gene. We have shown that the growth factor neuregulin-1 (NRG1) also contributes to human neurofibroma and MPNST pathogenesis and that outbred C57BL/6J × SJL/J transgenic mice overexpressing NRG1 in Schwann cells (P0-GGFβ3 mice) recapitulate the process of neurofibroma-MPNST progression. However, it is unclear whether NRG1 acts predominantly within NF1-regulated signaling cascades or instead activates other essential cascades that cooperate with NF1 loss to promote tumorigenesis. We now report that tumorigenesis is suppressed in inbred P0-GGFβ3 mice on a C57BL/6J background. To determine whether NRG1 overexpression interacts with reduced Nf1 or Trp53 gene dosage to "unmask" tumorigenesis in these animals, we followed cohorts of inbred P0-GGFβ3;Nf1+/−, P0-GGFβ3;Trp53+/− and control (P0-GGFβ3, Nf1+/− and Trp53+/−) mice for 1 year. We found no reduction in survival or tumors in control and P0-GGFβ3;Nf1+/− mice. In contrast, P0-GGFβ3;Trp53+/− mice died on average at 226 days, with MPNSTs present in 95 % of these mice. MPNSTs in inbred P0-GGFβ3;Trp53+/− mice arose de novo from micro-MPNSTs that uniformly develop intraganglionically. These micro-MPNSTs are of lower grade (WHO grade II-III) than the major MPNSTs (WHO grade III-IV); array comparative genomic hybridization showed that lower grade MPNSTs also had fewer genomic abnormalities. Thus, P0-GGFβ3;Trp53+/− mice represent a novel model of low- to high-grade MPNST progression. We further conclude that NRG1 promotes peripheral nervous system neoplasia predominantly via its effects on the signaling cascades affected by Nf1 loss.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24232507      PMCID: PMC3999224          DOI: 10.1007/s00401-013-1209-3

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  50 in total

1.  An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model.

Authors:  Karlyne M Reilly; Karl W Broman; Roderick T Bronson; Shirley Tsang; Dagan A Loisel; Emily S Christy; Zhonghe Sun; John Diehl; David J Munroe; Robert G Tuskan
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

2.  Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma.

Authors:  L Kluwe; R Friedrich; V F Mautner
Journal:  Genes Chromosomes Cancer       Date:  1999-03       Impact factor: 5.006

3.  Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.

Authors:  Jessica J Hawes; Robert G Tuskan; Karlyne M Reilly
Journal:  Neurogenetics       Date:  2007-01-11       Impact factor: 2.660

4.  Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.

Authors:  Feng-Chun Yang; Shi Chen; Travis Clegg; Xiaohong Li; Trent Morgan; Selina A Estwick; Jin Yuan; Waleed Khalaf; Sarah Burgin; Jeff Travers; Luis F Parada; David A Ingram; D Wade Clapp
Journal:  Hum Mol Genet       Date:  2006-07-11       Impact factor: 6.150

5.  The sec14 homology module of neurofibromin binds cellular glycerophospholipids: mass spectrometry and structure of a lipid complex.

Authors:  Stefan Welti; Sven Fraterman; Igor D'Angelo; Matthias Wilm; Klaus Scheffzek
Journal:  J Mol Biol       Date:  2006-11-18       Impact factor: 5.469

6.  Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3.

Authors:  R J Fiddes; D H Campbell; P W Janes; S P Sivertsen; H Sasaki; C Wallasch; R J Daly
Journal:  J Biol Chem       Date:  1998-03-27       Impact factor: 5.157

7.  Nestin expression as a new marker in malignant peripheral nerve sheath tumors.

Authors:  Satoko Shimada; Toyonori Tsuzuki; Makoto Kuroda; Tetsuro Nagasaka; Kazuo Hara; Emiko Takahashi; Seijun Hayakawa; Kenzo Ono; Nagako Maeda; Naoyoshi Mori; Peter B Illei
Journal:  Pathol Int       Date:  2007-02       Impact factor: 2.534

8.  Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues.

Authors:  C I Brannan; A S Perkins; K S Vogel; N Ratner; M L Nordlund; S W Reid; A M Buchberg; N A Jenkins; L F Parada; N G Copeland
Journal:  Genes Dev       Date:  1994-05-01       Impact factor: 11.361

9.  Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma.

Authors:  Stephen H Olsen; Dafydd G Thomas; David R Lucas
Journal:  Mod Pathol       Date:  2006-05       Impact factor: 7.842

10.  TP53 mutations are frequent in malignant NF1 tumors.

Authors:  E Legius; H Dierick; R Wu; B K Hall; P Marynen; J J Cassiman; T W Glover
Journal:  Genes Chromosomes Cancer       Date:  1994-08       Impact factor: 5.006

View more
  9 in total

1.  Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells.

Authors:  Jody Fromm Longo; Stephanie N Brosius; Steven L Carroll
Journal:  J Vis Exp       Date:  2021-08-25       Impact factor: 1.424

Review 2.  The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics.

Authors:  Steven L Carroll
Journal:  Am J Pathol       Date:  2015-12-28       Impact factor: 4.307

3.  Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis.

Authors:  Eric P Rahrmann; Branden S Moriarity; George M Otto; Adrienne L Watson; Kwangmin Choi; Margaret H Collins; Margaret Wallace; Beau R Webber; Colleen L Forster; Anthony E Rizzardi; Stephen C Schmechel; Nancy Ratner; David A Largaespada
Journal:  Am J Pathol       Date:  2014-05-13       Impact factor: 4.307

4.  Polycomb repression regulates Schwann cell proliferation and axon regeneration after nerve injury.

Authors:  Ki H Ma; Phu Duong; John J Moran; Nabil Junaidi; John Svaren
Journal:  Glia       Date:  2018-10-11       Impact factor: 7.452

5.  Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation.

Authors:  Angela C Hirbe; Sonika Dahiya; Dinorah Friedmann-Morvinski; Inder M Verma; D Wade Clapp; David H Gutmann
Journal:  Oncotarget       Date:  2016-02-16

Review 6.  Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies.

Authors:  AeRang Kim; Douglas R Stewart; Karlyne M Reilly; David Viskochil; Markku M Miettinen; Brigitte C Widemann
Journal:  Sarcoma       Date:  2017-05-16

7.  ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.

Authors:  Jody Fromm Longo; Stephanie N Brosius; Laurel Black; Stuart H Worley; Robert C Wilson; Kevin A Roth; Steven L Carroll
Journal:  Cell Commun Signal       Date:  2019-07-10       Impact factor: 7.525

8.  Distinct Tumor Microenvironments Are a Defining Feature of Strain-Specific CRISPR/Cas9-Induced MPNSTs.

Authors:  Amanda Scherer; Victoria R Stephens; Gavin R McGivney; Wade R Gutierrez; Emily A Laverty; Vickie Knepper-Adrian; Rebecca D Dodd
Journal:  Genes (Basel)       Date:  2020-05-23       Impact factor: 4.096

Review 9.  Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms.

Authors:  Jody F Longo; Shannon M Weber; Brittany P Turner-Ivey; Steven L Carroll
Journal:  Adv Anat Pathol       Date:  2018-09       Impact factor: 4.571

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.